Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/22/2025

Management Approach for Brain Lesions Identified on MRI

Initial Evaluation of Brain Lesions

  • MRI brain without and with IV contrast is the recommended imaging modality for evaluation of brain lesions, providing optimal characterization of lesion extent, tissue involvement, and associated features to guide appropriate management decisions, as recommended by the American College of Radiology 1, 2
  • For suspected intraaxial brain tumors, MRI without and with IV contrast should be performed to ensure accurate preoperative differential diagnosis, according to the American College of Radiology 2
  • MRI perfusion with IV contrast is an important adjunctive tool that provides additional information about tumor vascularity and blood-brain barrier permeability, as stated by the American College of Radiology 3
  • Contrast enhancement is crucial for identifying lesions with leaky vasculature, which is common in both primary and metastatic brain tumors, as noted by the American College of Radiology 3

Specific Imaging Protocols Based on Clinical Context

For Primary Brain Tumors

  • MRI without and with IV contrast is the preferred imaging modality for primary brain tumors, as recommended by the American College of Radiology 2
  • Standardized Brain Tumor Imaging Protocol (BTIP) should include precontrast T1, T2, DWI, and SWI sequences, according to the American College of Radiology 3
  • Perfusion MRI (particularly DSC-MRI) should be included in the protocol to aid in differential diagnosis, as stated by the American College of Radiology 3

For Metastatic Disease

  • MRI brain without and with IV contrast is recommended for screening and evaluation of brain metastases in patients with systemic malignancy, as recommended by the American College of Radiology 2
  • In lung cancer patients (particularly NSCLC), MRI brain without and with IV contrast is recommended for clinical stage II, III, or IV disease, even without neurologic symptoms, according to the American College of Radiology 4
  • MRI is more sensitive than CT for detecting small brain lesions and intracranial metastases, as noted by the American College of Radiology 4

Management Considerations for Different Types of Brain Lesions

Malignant Lesions

  • Typical findings of recurrent or progressive malignant disease on MRI include enhancing lesions crossing the midline, solid enhancement, and mass effect, as described by the American College of Radiology 2

Follow-up Imaging Recommendations

  • For previously treated brain tumors, MRI without and with IV contrast is essential for surveillance to detect recurrence or progression, as recommended by the American College of Radiology 2
  • For untreated cerebral aneurysms, follow-up should use the same imaging modality on which the aneurysm was initially found, according to the American College of Radiology 5

Common Pitfalls and Caveats

  • Pseudoprogression can mimic true tumor progression on conventional MRI and typically occurs within 3-6 months following completion of radiotherapy, as noted by the American College of Radiology 2
  • Enhancement is not a reliable metric in patients receiving bevacizumab therapy, as stated by the American College of Radiology 2
  • Conventional MRI has modest sensitivity and specificity (68% and 77%, respectively) for differentiating between progressive disease, pseudoprogression, and radiation necrosis, according to the American College of Radiology 2

REFERENCES

1

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025

2

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025

3

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025

5

acr appropriateness criteria<sup>®</sup> cerebrovascular disease. [LINK]

Journal of the American College of Radiology, 2017